http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/Article/list/572 Glaucoma topics including open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma & congenital glaucoma. Also imaging & treatment. Risk factors, disease progression, IOP, intraocular pressure, as well as endoscopic cyclophotocoagulation, trabeculectomy and shunts. 2009-11-21T17:46:36Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/World-Sight-Day-set-for-Oct-8/ArticleStandard/Article/detail/631236?contextCategoryId=572&ref=25 Three hundred events in more than 50 countries will mark this year's World Sight Day, Oct. 8. 2009-10-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412009/631236null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Aton-expands-programs-for-preservative-free-timolo/ArticleStandard/Article/detail/623228?contextCategoryId=572&ref=25 Aton Pharma has launched new education, distribution, sampling, and reimbursement programs for its preservative-free formulation of timolol maleate (Timoptic in Ocudose), which according to the company is the only preservative-free medication for glaucoma available in the United States. 2009-09-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/362009/623228null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Prostaglandin-analogue-monotherapys-long-duration-/ArticleStandard/Article/detail/627661?contextCategoryId=572&ref=25 Longer duration of use of monotherapy with prostaglandin analogues may be associated with lower annual costs of glaucoma treatment because adjunctive therapy is one of the primary factors affecting the cost of care, suggest findings of a retrospective analysis of a pharmacy claims database. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627661null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Glaucoma-minishunt-under-scleral-flap-demonstrates/ArticleStandard/Article/detail/627665?contextCategoryId=572&ref=25 A retrospective study analyzed outcomes of 345 consecutive eyes with the proprietary glaucoma minishunt (Ex-PRESS, Optonol) implanted, including 114 eyes having combined cataract surgery. During a mean follow-up of about 2 years, the implant provided effective IOP control whether used alone or in a combination procedure and was associated with few complications. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627665null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Canaloplasty-may-be-alternative-to-trabeculectomy/ArticleStandard/Article/detail/627657?contextCategoryId=572&ref=25 Non-penetrating Schlemm's canaloplasty may be a safe and effective alternative to standard trabeculectomy. A retrospective comparison study found no statistically significant differences in IOP reduction or medication usage at up to 1 year of follow-up. Adjunctive procedures and complications were similar in the two groups of patients, although no long-term hypotony was seen in the canaloplasty group. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627657null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Glaucoma-Latest-brimonidine-formulation-shows-impr/ArticleStandard/Article/detail/627653?contextCategoryId=572&ref=25 A meta-analysis based on data from 12-month trials including patients treated with brimonidine 0.1% with a preservative (Alphagan P 0.1% with Purite, Allergan) and patients using brimonidine 0.15% (Alphagan P 0.15%, Allergan) showed better systemic safety and tolerability with the lower-concentration product. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627653null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Glaucoma-Bimatoprost-tolerability-appears-to-be-en/ArticleStandard/Article/detail/627660?contextCategoryId=572&ref=25 The efficacy and tolerability of continuing latanoprost 0.005% (Xalatan, Pfizer) after 6 weeks of latanoprost monotherapy versus switching to bimatoprost 0.03% (Lumigan, Allergan) was investigated in an investigator-masked, randomized, parallel-group trial. The results showed good efficacy and tolerability in patients whose therapy was switched to bimatoprost and suggest that bimatoprost may be tolerated better after latanoprost pre-treatment. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627660null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Brimonidinetimolol-controls-IOP-in-clinical-settin/ArticleStandard/Article/detail/627652?contextCategoryId=572&ref=25 Brimonidine 0.2%/timolol 0.5% fixed-combination ophthalmic solution effectively lowers and controls IOP and is likely to be associated with increased patient adherence to therapy and decreased unwanted side effects such as ocular irritation, according to one ophthalmologist. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627652null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Preservative-free-IOP-lowering-medications-of-inte/ArticleStandard/Article/detail/627668?contextCategoryId=572&ref=25 Results of a survey of 124 ophthalmologists show interest in preservative-free formulations of IOP-lowering medications to preserve ocular surface health. Preservative-free timolol maleate (Timoptic in Ocudose, Aton Pharma) can be a good choice for appropriately selected patients, according to one ophthalmologist. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627668null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Glaucoma-Trabecular-micro-bypass-device-aids-IOP-r/ArticleStandard/Article/detail/627666?contextCategoryId=572&ref=25 Implantation of a trabecular micro-bypass (iStent, Glaukos Corp.) in patients with open-angle glaucoma who are undergoing cataract surgery represents an alternative surgical approach that can provide clinically significant reductions in IOP and use of ocular hypotensive medications. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627666null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Endocyclophotocoagulation-beneficial-for-those-wit/ArticleStandard/Article/detail/627664?contextCategoryId=572&ref=25 Endocyclophotocoagulation (ECP) can be performed easily in patients with medically controlled glaucoma who are undergoing cataract surgery, to provide additional IOP lowering and reduce medication use. Misunderstanding that ECP is a completely different procedure than transscleral cyclodestruction contributes to under-use of this very safe procedure, according to one ophthalmologist. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627664null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Retinal-photographs-facilitate-glaucoma-diagnosis-/ArticleStandard/Article/detail/627669?contextCategoryId=572&ref=25 New software (MatchedFlicker, EyeIC) uses time series retinal photographs to convert change into motion and could improve the accuracy and speed of detecting glaucomatous progression. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627669null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Glaucoma-Hyperemia-a-common-cause-for-medication-c/ArticleStandard/Article/detail/627662?contextCategoryId=572&ref=25 Hyperemia is one of the main reasons why patients with glaucoma do not adhere to or persist with their topical therapeutic regimen. Patients end up switching to another possibly more tolerable medication, and the changing of medications has significant financial implications. Latanoprost has the lowest incidence of hyperemia among the prostaglandin analogs. Patient adherence is crucial in a chronic progressive disease such as glaucoma, where non-adherence can lead to visual loss and decline in quality of life, creating societal health and economic burdens. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627662null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Ocular-perfusion-pressure-is-a-glaucoma-risk-accor/ArticleStandard/Article/detail/627663?contextCategoryId=572&ref=25 Recent literature has identified ocular perfusion pressure as a glaucoma risk factor. Ophthalmologists need to be aware of the growing evidence supporting this theory, according to one expert. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627663null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/NicOx-and-Pfizer-sign-agreement-for-PF-03187207/ArticleStandard/Article/detail/619794?contextCategoryId=572&ref=25 NicOx has signed an agreement with Pfizer to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open-angle glaucoma and ocular hypertension, according to a prepared statement. 2009-08-19T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/342009/619794null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/NicOx-to-reacquire-from-Pfizer-rights-to-experimen/ArticleStandard/Article/detail/617973?contextCategoryId=572&ref=25 NicOx announced an agreement to reacquire the development and commercialization rights to an experimental glaucoma medicine from partner company Pfizer. 2009-08-11T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/332009/617973null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/SOLX-receives-clearance-for-glaucoma-implant-use-i/ArticleStandard/Article/detail/615732?contextCategoryId=572&ref=25 SOLX has received clearance from Health Canada for the use of its 24-karat gold implant (SOLX Gold Shunt) during glaucoma surgery. 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/615732null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Contact-lenses-effective-for-medication-delivery-a/ArticleStandard/Article/detail/614393?contextCategoryId=572&ref=25 Drug-releasing contact lenses may provide correct and consistent dosages of medication for patients, according to findings published in Investigative Ophthalmology & Visual Science. 2009-07-28T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/614393null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Alcon-discontinues-development-of-anecortave-aceta/ArticleStandard/Article/detail/610827?contextCategoryId=572&ref=25 Alcon Inc. announced it has discontinued development of anecortave acetate for the reduction of IOP associated with glaucoma. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610827null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/Glaucoma-progression-software-receives-clearance-f/ArticleStandard/Article/detail/606851?contextCategoryId=572&ref=25 Software (MatchedFlicker, EyeIC) that monitors the advent and progression of glaucoma through retinal photography has received FDA 510(k) clearance. 2009-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/606851null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/A-clinical-role-for-canaloplasty-is-established-by/ArticleStandard/Article/detail/606429?contextCategoryId=572&ref=25 Canaloplasty with placement of a tensioning suture is indicated for the surgical management of open-angle glaucoma. Results from a multicenter study show that after 2 years, it continues to provide a 35% reduction in IOP, with a better safety profile than trabeculectomy and without bleb-related complications. 2009-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/606429null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Gibson-appointed-director-of-development-for-Glauc/ArticleStandard/Article/detail/605751?contextCategoryId=572&ref=25 The Glaucoma Research Foundation announced the addition of Candler Gibson as the new director of development. 2009-06-22T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/605751null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Gene-directed-therapy-in-glaucoma-may-have-future-/ArticleStandard/Article/detail/602859?contextCategoryId=572&ref=25 Researchers studying the molecular genetics of glaucoma are discovering new genes by applying high-powered technologies to their analysis of family pedigrees and looking for clues in animal models. These genetic discoveries are moving this field toward clinical applications. 2009-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/602859null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Latanoprost-solution-for-glaucoma-is-included-in-p/ArticleStandard/Article/detail/602842?contextCategoryId=572&ref=25 Newly unemployed Americans and their families who have lost their health insurance coverage and who are taking Pfizer branded medicines, including latanoprost ophthalmic solution (Xalatan), may be eligible for free medicine under a new patient assistance program launched by the manufacturer. 2009-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/602842null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/OCT-system-with-RNFL-and-macular-databases-approve/ArticleStandard/Article/detail/602910?contextCategoryId=572&ref=25 A new optical coherence tomography (OCT) software application (Cirrus [high-definition] HD-OCT, Carl Zeiss Meditec) has been cleared by the FDA for commercial distribution. 2009-06-11T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/602910null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Glaucoma-medication-adherence-linked-to-age-and-et/ArticleStandard/Article/detail/601974?contextCategoryId=572&ref=25 Studies covering a range of chronic disease consistently show that only about 70% of prescribed medications are taken. Patients with glaucoma may not take their eye drops because they often have no pain, few symptoms, and treatment benefits are apparent over years rather than immediately. 2009-06-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/232009/601974null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/Paradigm-Medical-seeks-upgraded-CPT-code-for-its-t/ArticleStandard/Article/detail/600354?contextCategoryId=572&ref=25 Paradigm Medical Industries Inc. has announced its plans to upgrade its Current Procedural Terminology (CPT) code (0189T) for its tonometer (Ocular Blood Flow Analyzer) from the American Medical Association from an investigational level (Class III). 2009-05-28T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/600354null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Open-angle-glaucoma-treatment-includes-a-newer-via/ArticleStandard/Article/detail/599648?contextCategoryId=572&ref=25 Ab interno trabeculectomy using a minimally invasive proprietary device (Trabectome, Neomedix) aims to re-establish physiologic aqueous outflow by removing a strip of angle tissue. It may be a reasonable option in eyes with a good gonioscopic view in which IOP in the 14 to 16 mm Hg range is an acceptable target. 2009-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/599648null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Glaucoma-Endolaser-cyclophotocoagulation-shows-pro/ArticleStandard/Article/detail/599651?contextCategoryId=572&ref=25 Endolaser cyclophotocoagulation (ECP) appears to be an effective treatment for a variety of indications, including several types of glaucoma as well as combined glaucoma and phacoemulsification cases. The surgeon's ability to visualize and target the ciliary processes with ECP eliminates collateral tissue damage and reduces the risk of side effects such as inflammation and pain. 2009-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/599651null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Tube-versus-Trabeculectomy-Study-suggests-expanded/ArticleStandard/Article/detail/599637?contextCategoryId=572&ref=25 Three-year safety and efficacy results from the Tube versus Trabeculectomy Study show a persistent benefit of tube shunt surgery over trabeculectomy through the third postoperative year. The findings suggest that the role of tube shunt surgery should be expanded beyond refractory glaucomas at high risk of failure with standard filtering surgery. 2009-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/599637null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Paradigm-redefines-its-role-within-glaucoma-ophtha/ArticleStandard/Article/detail/595355?contextCategoryId=572&ref=25 Paradigm Medical Industries said it has plans to reorganize and reposition itself within the ophthalmic market. Plans include engineering improvements to many of its products and an assessment of its operations efforts. 2009-04-28T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/182009/595355null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Perimetry-software-measures-functional-progression/ArticleStandard/Article/detail/597259?contextCategoryId=572&ref=25 The newest version of proprietary software (Guided Progression Analysis, Carl Zeiss Meditec) to measure the functional progression of glaucoma combines event and trend analyses and enables faster, more quantitative evaluation of change in visual field than that permitted by older methods, according to one ophthalmologist. Use of the software requires a particular, newer perimeter (Humphrey Field Analyzer II-i, Carl Zeiss Meditec), and clinical correlation is advised. 2009-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/597259null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/SD-OCT-provides-improvement-in-imaging-compared-wi/ArticleStandard/Article/detail/597258?contextCategoryId=572&ref=25 Spectral-domain optical coherence tomography (SD-OCT) represents an improvement in imaging compared with time-domain OCT and, therefore, the potential for improved patient care. Proprietary technology (3D OCT 1000, Topcon Medical Systems) is easy to use and has versatile software, according to one ophthalmologist. The choice of any SD-OCT unit, however, must be based on an analysis of an individual practice's needs. 2009-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/597258null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Mini-glaucoma-shunt-rivals-trabeculectomy-results-/ArticleStandard/Article/detail/597255?contextCategoryId=572&ref=25 The mini-glaucoma shunt (Ex-Press, Optonol) appears to be an effective procedure compared with standard trabeculectomy, as it shows a higher efficiency with minimal inflammation and lower rates of postoperative hypotony and its sequelae. Although both approaches demonstrate very similar IOP control in the long-term, less postoperative adverse events are seen with implantation of the shunt. 2009-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/597255null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Study-High-IOP-linked-to-RNFL-loss-in-progression-/ArticleStandard/Article/detail/597249?contextCategoryId=572&ref=25 Elevated IOP accelerates retinal nerve fiber layer (RNFL) loss and increases the risk that glaucoma will progress, according to an observational cohort study of 204 patients recruited from the Diagnostic Innovations in Glaucoma Study. 2009-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/597249null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Physician-still-most-important-diagnostic-imager/ArticleStandard/Article/detail/597245?contextCategoryId=572&ref=25 The clinical exam remains the key to ophthalmologists' decision-making related to the diagnosis and determination of progression of glaucoma. "Baseline" technology in ophthalmology practices includes the slit lamp, some lenses, a gonio prism, an automated perimeter, a pachymeter, and optic nerve imaging capability. Other technology, however—such as confocal scanning laser ophthalmoscopy; nerve fiber layer imaging devices capable of scanning laser polarimetry and optical coherence tomography (OCT); and some anterior segment imaging technologies, including ultrasound biomicroscopy and anterior segment OCT—do not yet have absolute sensitivity and specificity and serve as aids to, not replacements for, the ophthalmologist. 2009-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/597245null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Efficiency-key-when-managing-busy-glaucoma-practic/ArticleStandard/Article/detail/597238?contextCategoryId=572&ref=25 The future will bring an influx of glaucoma patients due to an aging population as well as more patients with angle-closure glaucoma, stemming from an influx of immigrants. Increasing the efficiency of the clinical and business sides of the glaucoma practice is a must for survival in this changing environment. Some procedures that can increase cost efficiency include gonioscopy and tailoring visual field testing to the patient. 2009-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/597238null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/Ophthalmologists-cite-benefits-of-preservative-fre/ArticleStandard/Article/detail/593318?contextCategoryId=572&ref=25 In a recent survey of U.S. ophthalmologists, 97% believe preservative-free glaucoma medications can enhance the ocular comfort of patients with glaucoma, whereas 86% believe that preservative-free glaucoma medications can enhance patient quality of life. 2009-04-14T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/162009/593318null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Cataract/ASCRS-Two-year-data-Canaloplasty-combined-with-pha/ArticleStandard/Article/detail/591748?contextCategoryId=572&ref=25 San Francisco—The combination of canaloplasty and phacoemulsification surgery in patients who have both cataracts and primary open-angle glaucoma (POAG) results in a dramatic decrease in both IOP and the number of anti-glaucoma medications patients must take. Bradford J. Shingleton, MD, a glaucoma and cataract specialist with Ophthalmic Consultants of Boston, presented 2-year results of an ongoing prospective, randomized international study of canaloplasty in patients with POAG who also presented with a visually significant cataract. 2009-04-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152009/591748null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ASCRS-Non-penetrating-canaloplasty-may-offer-safe-/ArticleStandard/Article/detail/591712?contextCategoryId=572&ref=25 San Francisco— Non-penetrating canaloplasty may provide an effective and safe alternative to standard trabeculectomy in patients with primary open-angle glaucoma (POAG), according to Diamond Y. Tam, MD, University of Toronto. 2009-04-04T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152009/591712null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma+News/ASCRS-Ways-to-reduce-the-pressure-of-the-recession/ArticleStandard/Article/detail/591532?contextCategoryId=572&ref=25 San Francisco—If you had a very ill patient, you would examine his or her vital signs frequently. The same holds true when the "patient" is the U.S. economy, said John B. Pinto, of the ophthalmic practice management consulting firm J. Pinto & Associates. 2009-04-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/591532null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/ASCRS-Three-experts-weigh-in-with-advice-for-the-p/ArticleStandard/Article/detail/591531?contextCategoryId=572&ref=25 San Francisco—What advice would you give to President Obama to help navigate health-care reform? Three people well acquainted with the challenges that the president will face answered that question here at Glaucoma Day. 2009-04-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/591531null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/ASCRS-Small-persistent-steps-will-bring-clinical-a/ArticleStandard/Article/detail/591530?contextCategoryId=572&ref=25 San Francisco—"If you wanted to be at the start of a major change in how we do things in glaucoma, you're there," said Richard A. Lewis, MD, who spoke during the Stephen A. Obstbaum, MD, Honored Lecture at Glaucoma Day. 2009-04-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/591530null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Glaucoma-patients-care-A-look-into-the-future/ArticleStandard/Article/detail/593681?contextCategoryId=572&ref=25 A common sentiment in the United States and other countries is that the health-care system is broken. Rather than dwell on the real problems besetting health care, however, it is instead suggested that ophthalmologists take advantage of the challenging environment to lead the way toward changes that will improve care, meet patient needs, and re-establish the professionalism of medicine and medical care. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/162009/593681null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/A-neovascular-glaucoma-option-is-anti-vascular-end/ArticleStandard/Article/detail/593682?contextCategoryId=572&ref=25 Better understanding of the relationship between neovascular glaucoma and the elaboration of vascular endothelial growth factor (VEGF) has led to a new therapeutic option, intravitreal injection of anti-VEGF agents. Although a limited number of studies on this novel approach have been published, the reports are encouraging. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/162009/593682null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/In-glaucoma-patients-punctal-plug-delivery-system-/ArticleStandard/Article/detail/593683?contextCategoryId=572&ref=25 Early studies of a punctal plug delivery system for the treatment of glaucoma and ocular hypertension show promising results. The device was effective at lowering IOP, and no safety concerns were apparent. The system is envisioned as one solution to the problem of patient adherence with a regimen of daily eye drops for glaucoma treatment. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/162009/593683null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/American-Glaucoma-Society-sees-record-attendance-g/ArticleStandard/Article/detail/593668?contextCategoryId=572&ref=25 The 2009 annual meeting of the American Glaucoma Society (AGS), March 5 to 8, experienced record attendance, according to officers of the organization, with 619 members and an additional 75 attendees participating. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/162009/593668null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Glaucoma-linked-to-several-different-gene-variatio/ArticleStandard/Article/detail/588998?contextCategoryId=572&ref=25 While researching the long-suspected gene linked to glaucoma, WDR36, Michael Walter, PhD, and team discovered that the gene STL1 is only one of many other genes in which mutations must take place in order for WDR36 to cause glaucoma. 2009-03-24T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/132009/588998null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Feature+Articles/A-fluttering-of-hope-Bimatoprost-solution-lengthen/ArticleStandard/Article/detail/587673?contextCategoryId=572&ref=25 Ophthalmologists looking for a new avenue for growth might want to consider adding bimatoprost ophthalmic solution 0.03% (Latisse, Allergan) to their repertoire. 2009-03-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/122009/587673null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/WGD-Glaucoma-activities-planned-across-United-Stat/ArticleStandard/Article/detail/586552?contextCategoryId=572&ref=25 United States—Many World Glaucoma Day activities occurred across the United States. 2009-03-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/586552null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/WGD-Vision-community-unites-to-observe-WGD-on-Capi/ArticleStandard/Article/detail/586663?contextCategoryId=572&ref=25 Washington, DC—To recognize the second annual World Glaucoma Day (WGD), the Association for Eye and Vision Research (AEVR) sponsored a March 10 Capitol Hill briefing to educate Members of Congress and their staffs. 2009-03-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/586663null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/WGD-UN-officials-screened-for-glaucoma-in-observan/ArticleStandard/Article/detail/586542?contextCategoryId=572&ref=25 New York—In observance of the second annual World Glaucoma Day, ambassadors, deputy ambassadors, and the secretary general and his staff at the United Nations headquarters here were invited to a free glaucoma screening Wednesday, which was hosted by the New York Eye and Ear Infirmary and The Glaucoma Foundation. 2009-03-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/586542null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/WGD-Italian-campaign-to-abolish-red-tape-help-pati/ArticleStandard/Article/detail/586665?contextCategoryId=572&ref=25 Rome—Tiziana Fattori, MD, of Per Vedere Fatti Vedere onlus in Italy explained the reasons behind the launch of a campaign to abolish bureaucratic procedures inhibiting patients from undertaking treatment for glaucoma. 2009-03-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/586665null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/WGD-Pfizer-Allergan-support-World-Glaucoma-Day/ArticleStandard/Article/detail/586546?contextCategoryId=572&ref=25 New York—To help celebrate the second annual World Glaucoma Day, government representatives, eye-care professionals, patient groups, and members of the industry throughout the world offered their support through specific programs designed to increase global awareness of glaucoma and the importance of early detection and successful management. 2009-03-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/586546null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/WGD-Successful-awareness-of-glaucoma-generated-mor/ArticleStandard/Article/detail/586642?contextCategoryId=572&ref=25 New York—As president and chief executive officer of the World Glaucoma Foundation, and president of the World Glaucoma Patient Association (WGPA), Scott R. Christensen has been extensively involved in planning and coordinating efforts around the world to raise awareness about the critical need to detect glaucoma in its earliest stages possible. 2009-03-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/586642null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/WGD-activities-abound-in-Central-and-Latin-America/ArticleStandard/Article/detail/586662?contextCategoryId=572&ref=25 Latin America—World Glaucoma Day events occurred across Latin and Central America. In Argentina, Maria Carrasco, MD, of Hospital Perrupato granted radio interviews about glaucoma in Mendoza. Television, radio, and newspaper interviews also were scheduled in San Pedro, Argentina (Jorge Marceillac, MD), Santa Cruz, and Buenos Aires. 2009-03-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/586662null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/WGD-Motion-Displacement-Test-on-show-for-WGD/ArticleStandard/Article/detail/586664?contextCategoryId=572&ref=25 London—In observance of World Glaucoma Day (WGD), the Motion Displacement Test (MDT), developed by Moorfields Eye Hospital, London, in partnership with University College London (UCL) Institute of Ophthalmology and City University London was on display as part of a demonstration of the latest glaucoma diagnostic equipment. 2009-03-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/586664null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/WGD-Glaucoma-awareness-screenings-continue-across-/ArticleStandard/Article/detail/586667?contextCategoryId=572&ref=25 European Union—Public screenings were scheduled to take place on World Glaucoma day today at a variety of venues including private practices and hospitals in Austria, Belgium, Bulgaria, Greece, Italy, Spain, and Switzerland, in observance of World Glaucoma Day. 2009-03-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/586667null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/WGD-Second-annual-WGD-observance-expected-to-surpa/ArticleStandard/Article/detail/586548?contextCategoryId=572&ref=25 New York—The World Glaucoma Association and the World Glaucoma Patient Association (WGPA) are teaming up with governmental agencies, health-care providers, eye-care industry members, and others to sponsor the second annual World Glaucoma Day (WGD) today, which is expected to surpass last year's efforts. 2009-03-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/586548null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Trend-event-analyses-have-distinct-advantages/ArticleStandard/Article/detail/585533?contextCategoryId=572&ref=25 San Diego—When it comes to assessment of progression of glaucoma, trend analysis and event analysis have distinct advantages, said Joseph Caprioli, MD. He is the David May II Professor of Ophthalmology, chief of the glaucoma division, and director of the glaucoma basic science and clinical laboratories at the Jules Stein Eye Institute, Los Angeles. 2009-03-06T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/102009/585533null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/World-Glaucoma-Day-set-for-March-12/ArticleStandard/Article/detail/579954?contextCategoryId=572&ref=25 The World Glaucoma Association and the World Glaucoma Patient Association have set March 12 as the second annual World Glaucoma Day. 2009-02-05T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/062009/579954null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Pfizer-to-acquire-Wyeth-for-68-billion/ArticleStandard/Article/detail/579945?contextCategoryId=572&ref=25 Pfizer will acquire Wyeth in a cash-and-stock transaction valued at $50.19 per share, or a total of about $68 billion, as of the Jan. 26 announcement of the planned merger. 2009-02-05T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/062009/579945null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Micropulse-laser-for-glaucoma-may-hold-promise-as-/ArticleStandard/Article/detail/580307?contextCategoryId=572&ref=25 In a small pilot study with limited follow-up, early application of micropulse laser trabeculoplasty (MLT) using a specific diode laser (IQ810, Iridex Corp.) appeared promising. Use of this multifunctional laser may have practical advantages in a clinical setting. Further study of the technology is needed to determine the role of MLT in the treatment of glaucoma. 2009-02-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/062009/580307null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/Glaucoma-shunt-clinical-trial-to-assess-safety-and/ArticleStandard/Article/detail/577352?contextCategoryId=572&ref=25 A clinical trial has begun that will assess the safety and efficacy of a glaucoma shunt (Aquashunt, Opko Health) designed to lower IOP in patients with refractory open-angle glaucoma. 2009-01-26T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577352null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Two-physicians-honored-at-GRF-benefit/ArticleStandard/Article/detail/576663?contextCategoryId=572&ref=25 During their 31st anniversary benefit Jan. 28, the Glaucoma Research Foundation will honor two physicians for their contributions to glaucoma research. 2009-01-20T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/042009/576663null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Brimonidinetimolol-combination-fares-well-in-study/ArticleStandard/Article/detail/577643?contextCategoryId=572&ref=25 The fixed combination of brimonidine and timolol (Combigan, Allergan) provided greater overall patient comfort, and IOP decreased significantly, compared with the fixed combination of dorzolamide and timolol (Cosopt, Merck & Co.) in patients with primary open-angle glaucoma. 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577643null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Tomographs-best-used-as-one-of-several-sources/ArticleStandard/Article/detail/577639?contextCategoryId=572&ref=25 The retinal tomographer, a quantitative imaging instrument, is useful in both diagnosis and monitoring of ocular hypertension, suspected glaucoma, and early glaucoma. 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577639null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Normal-tension-glaucoma-is-defined-as-a-type-of-pr/ArticleStandard/Article/detail/577637?contextCategoryId=572&ref=25 Normal-tension glaucoma (NTG) is a form of primary open-angle glaucoma (POAG) in which there is no known history of statistically elevated IOP; however, the definition of an upper limit of normal IOP is arbitrary. POAG is a multifactorial disease process with pressure-dependent and pressure-independent etiologic factors. In NTG, the pressure-independent factors likely play a more substantial role. 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577637null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/Glaucoma-technology-driven-adherence-program-to-be/ArticleStandard/Article/detail/575647?contextCategoryId=572&ref=25 A clinical trial will be conducted by Johns Hopkins University's Wilmer Eye Institute on patient adherence and clinical outcomes for people with glaucoma using technology (Memotext). 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/032009/575647null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/X-GEN-receives-approval-for-drug/ArticleStandard/Article/detail/577633?contextCategoryId=572&ref=25 X-GEN Pharmaceuticals Inc. will begin marketing injectable acetazolamide for indications including open-angle glaucoma, secondary glaucoma, and preoperative use for the treatment of acute angle-closure glaucoma. 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577633null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Glaucoma-effectively-identified-by-scanning-laser/ArticleStandard/Article/detail/577645?contextCategoryId=572&ref=25 A scanning laser polarimetry device, which examines the retinal nerve fiber layer, is a beneficial diagnostic tool for glaucoma suspects because it targets the area where the earliest damage from glaucoma is likely to be seen. It also is valuable in monitoring stability or progression in patients with established disease. 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577645null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Bimatoprost-gets-nod-for-hypotrichosis/ArticleStandard/Article/detail/577632?contextCategoryId=572&ref=25 Allergan has received FDA approval for its 0.03% bimatoprost ophthalmic solution (Latisse) as a novel treatment for hypotrichosis of the eyelashes. 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577632null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Frequency-doubling-technology-threshold-test-effec/ArticleStandard/Article/detail/577642?contextCategoryId=572&ref=25 Frequency-doubling technology (FDT) has a role as a diagnostic and monitoring instrument for glaucoma, although it may be best used to complement the use of other testing methods, particularly with the newer version of this technology. Studies suggest that the FDT may detect early glaucoma in a different subgroup of patients than other testing devices, and long-term studies will be needed to confirm its effectiveness in detection of progression. 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577642null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Glaucoma-valve-anterior-versus-posterior-placement/ArticleStandard/Article/detail/577641?contextCategoryId=572&ref=25 Whether opting for an anterior or posterior approach when placing a glaucoma valve, both procedures appear to have similar success in lowering IOP and similar complication profiles, according to the results of a recent study. Nevertheless, some experts believe that the anterior approach may be more advantageous. 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577641null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Prostaglanin-analogue-study-Benzalkonium-chloride-/ArticleStandard/Article/detail/577644?contextCategoryId=572&ref=25 Safety data from a multicenter, double-masked, randomized clinical trial comparing the three commercially available prostaglandin analogue IOP-lowering medications containing benzalkonium chloride (BAK) were analyzed to investigate a possible relationship between BAK content and incidence of ocular adverse events. Latanoprost 0.005% (Xalatan, Pfizer), which exposes patients to the highest daily BAK dose, was associated with significantly lower rates of both ocular adverse events and study medication-related adverse events compared with bimatoprost 0.03% (Lumigan, Allergan) and travoprost 0.004% (Travatan, Alcon Laboratories). 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577644null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Glaucoma-medication-a-factor-in-ocular-surface-dis/ArticleStandard/Article/detail/577638?contextCategoryId=572&ref=25 Due to the frequent coexistence of ocular surface disease and glaucoma in older patients, clinicians should take steps to reduce the potentially damaging effects on the ocular surface of long-term use of glaucoma medication. Reducing the number of medications when possible and choosing those that do not contain the preservative benzalkonium chloride is an approach that may be beneficial in some patients. 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577638null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Tonometer-can-provide-accurate-IOP-levels-during-s/ArticleStandard/Article/detail/577640?contextCategoryId=572&ref=25 A recent study shows that although the Goldmann applanation tonometer (GAT) is considered to be the standard in detecting eyes with elevated IOP and, therefore, glaucoma, a newer tonometer (Ocular Response Analyzer [ORA], Reichert) appears to be more effective. It also is suggested that glaucoma screening threshold pressure should be lowered from the current 21 mm Hg to 18 mm Hg, which may allow ophthalmologists to more effectively detect glaucoma in their patients. 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577640null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/Glaucoma-patients-twice-as-likely-to-have-reading-/ArticleStandard/Article/detail/575135?contextCategoryId=572&ref=25 A recent study found that people with bilateral glaucoma read 29 words per minute slower than those without glaucoma and were twice as likely to have a reading impairment. 2009-01-13T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/032009/575135null HTML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Glaucoma-therapies-technology-expand-in-08/ArticleStandard/Article/detail/572051?contextCategoryId=572&ref=25 Although 2008 was not a year of major advances in glaucoma, it still was a time of progress. Structural imaging devices continue to improve; more data are emerging on surgical alternatives to trabeculectomy; and some novel medical therapies appear interesting, even though they are just in very early stages of clinical investigation. Perspectives on recent developments and current controversies are discussed. 2008-12-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/512008/572051null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Glaucoma-progression-Monitor-disease-with-multi-st/ArticleStandard/Article/detail/568128?contextCategoryId=572&ref=25 As understanding of the multifaceted nature of glaucoma continues to grow, the steps practitioners need to take to monitor progression of the disease evolve. Key steps to take to monitor progression include confirming with repeat testing any visual function loss, remembering that structural measurements have variability, and using structural and functional testing together. 2008-12-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/482008/568128null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Glaucoma-20-year-incidence-may-be-estimated-by-mat/ArticleStandard/Article/detail/568127?contextCategoryId=572&ref=25 Using a mathematical model, investigators have estimated that people with ocular hypertension have a nearly 30% risk of developing glaucoma over 20 years, adjusting for the competing risk of mortality. Among ocular hypertensive patients aged more than 70 years, however, a 90% risk of mortality exists over that 20-year period, suggesting that preventive treatment would have little benefit. 2008-12-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/482008/568127null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Glaucoma-drug-being-studied-by-Inspire/ArticleStandard/Article/detail/568122?contextCategoryId=572&ref=25 Inspire Pharmaceuticals Inc. has initiated a phase I clinical trial of INS117548 ophthalmic solution for the treatment of glaucoma. 2008-12-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/482008/568122null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Role-identified-for-glaucoma-gene-and-signaling-pa/ArticleStandard/Article/detail/560428?contextCategoryId=572&ref=25 Another piece of the puzzle of the mechanism involved in the elevation of IOP has been identified with the discovery of the role of the gene sFRP-1 in the Wnt signaling pathway. 2008-11-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/432008/560428null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Mini-glaucoma-shunt-viable-surgical-alternative/ArticleStandard/Article/detail/559871?contextCategoryId=572&ref=25 Surgical outcomes were compared in a retrospective study of 76 eyes with a miniature glaucoma shunt (Ex-PRESS, Optonol) implanted and 77 eyes that underwent standard trabeculectomy. The two procedures were associated with similar IOP-lowering efficacy, but the shunt procedure had a benefit for reducing the risk of hypotony. 2008-10-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/432008/559871null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Ab-interno-trabeculectomy-with-novel-ablative-devi/ArticleStandard/Article/detail/559872?contextCategoryId=572&ref=25 Outcomes data for ab-interno trabeculectomy with a novel ablative device (Trabectome, NeoMedix) to ablate thermally the trabecular meshwork consist of case series. So far, this procedure has been associated with favorable IOP lowering, but a direct comparison with standard trabeculectomy is needed, according to one glaucoma specialist. 2008-10-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/432008/559872null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Trabecular-micro-bypass-stent-shows-favorable-safe/ArticleStandard/Article/detail/556850?contextCategoryId=572&ref=25 A trabecular bypass micro stent (iStent, Glaukos) was developed to restore fully natural physiologic outflow in glaucomatous eyes by allowing flow of aqueous from the anterior chamber into Schlemm's canal. 2008-10-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412008/556850null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Modification-minimizes-complications-of-trabeculec/ArticleStandard/Article/detail/556851?contextCategoryId=572&ref=25 Implantation of a miniature glaucoma device (Ex-PRESS R-50, Optonol) under a scleral flap is a modification of trabeculectomy that appears to provide similar IOP-lowering efficacy but with fewer complications. 2008-10-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412008/556851null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Evolving-definition-of-glaucoma-will-alter-treatme/ArticleStandard/Article/detail/556853?contextCategoryId=572&ref=25 Once thought to be a disease characterized solely by elevated IOP, the definition of glaucoma has been evolving to more accurately portray the disease's true nature. 2008-10-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412008/556853null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Need-for-accurate-continuous-IOP-measurements-impe/ArticleStandard/Article/detail/556852?contextCategoryId=572&ref=25 Current IOP measurement techniques have limited accuracy and do not allow for 24-hour monitoring. A system based on a small, implantable passive transducer and external probe is being developed to address these limitations. 2008-10-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412008/556852null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/24-hour-IOP-control-key-to-minimizing-glaucoma-pro/ArticleStandard/Article/detail/548857?contextCategoryId=572&ref=25 Research supports that 24-hour IOP control is critical to minimizing glaucoma progression. Practitioners are encouraged to review the choices for primary and adjunctive medical therapy based on the ability to control pressures during both the day and nocturnal periods. 2008-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372008/548857null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/IOP-safely-and-significantly-lowered-by-ECP-plus-p/ArticleStandard/Article/detail/548862?contextCategoryId=572&ref=25 Results of a retrospective chart review including 101 consecutive eyes that underwent endoscopic cyclophotocoagulation (ECP) combined with phacoemulsification and IOL implantation document the safety of this procedure for lowering IOP. A subgroup analysis suggests that ECP may have a unique application in eyes with chronic angle-closure glaucoma and plateau iris. 2008-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372008/548862null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Long-term-use-of-latanoprost-does-not-pose-increas/ArticleStandard/Article/detail/548860?contextCategoryId=572&ref=25 Outcomes of a 5-year study, initiated when the first prostaglandin analog became available, showed that latanoprost (Xalatan, Pfizer) does not increase the frequency of corneal erosions during long-term glaucoma treatment when compared with other forms of pressure-lowering medication. 2008-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372008/548860null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/SLT-lowers-IOP-with-favorable-safety-says-clinicia/ArticleStandard/Article/detail/548875?contextCategoryId=572&ref=25 Selective laser trabeculoplasty offers safe and effective treatment for patients with primary open-angle glaucoma and other, more difficult glaucomas, according to one ophthalmologist. It might be a reasonable first-line intervention in some situations. 2008-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372008/548875null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Device-shows-promise-for-glaucoma-surgery/ArticleStandard/Article/detail/548869?contextCategoryId=572&ref=25 A miniature shunt (Ex-Press, Optonol) is as effective as standard trabeculectomy procedures in the lowering of IOP in patients with glaucoma, according to a retrospective review. The advantages of implementation of the device over standard trabeculectomy include a greater decrease in the postoperative medications taken by patients, lower levels of hypotony occurrence, and a predictable, even flow reduction of aqueous fluid from the subconjunctival space. 2008-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372008/548869null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Modified-OCT-device-provides-higher-resolution-ima/ArticleStandard/Article/detail/548868?contextCategoryId=572&ref=25 A modified version of a commercially available high-definition optical coherence tomography (OCT) device, adapted for imaging the anterior chamber angle, was able to provide higher-resolution images than current OCT devices and help investigators identify a new anatomic landmark. If this instrument is developed commercially, it could become a new gold standard for diagnosis of angle-closure glaucoma. 2008-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372008/548868null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/New-preservative-does-not-alter-efficacy-of-travop/ArticleStandard/Article/detail/548863?contextCategoryId=572&ref=25 A new formulation of travoprost (Travatan Z, Alcon Laboratories) containing an ionic-buffered preservative (sofZia), and the older formulation (Travatan), preserved with benzalkonium chloride (BAK), had similar IOP-lowering effects in a group of patients who began treatment with the original drop then switched to the newer drug. The ionic-buffered agent is intended to be less toxic to the ocular surface than BAK, which could be significant in long-term glaucoma therapy. 2008-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372008/548863null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Exam-therapy-adherence-vital-after-initial-screeni/ArticleStandard/Article/detail/548858?contextCategoryId=572&ref=25 Glaucoma screenings can help identify people who may have the disease to encourage them to receive care. Ophthalmologists must stress to participants the importance of seeking that care and adhering to any subsequently prescribed therapy. Vision loss from glaucoma occurs with the death of the retinal ganglia cells that travel from the optic nerve to the brain. Therefore, a current goal is to identify sick cells that try to "rescue" them by lowering IOP. For the future, however, the hope is to be able to regenerate cells that have been sickened by the disease. 2008-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372008/548858null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Canaloplasty-new-contender-in-glaucoma-surgery-are/ArticleStandard/Article/detail/548872?contextCategoryId=572&ref=25 Canaloplasty with tensioning suture placement is an FDA-approved technique for the surgical management of open-angle glaucoma. This nonpenetrating procedure obviates the need for a bleb and has been associated with good IOP control after 2 years of follow-up. The accumulating data and a successful training program are contributing to increasing interest. 2008-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372008/548872null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Newer-glaucoma-procedures-may-threaten-the-longsta/ArticleStandard/Article/detail/548874?contextCategoryId=572&ref=25 Trabeculectomy remains the most commonly performed surgical glaucoma procedure. However, interest in identifying alternatives involving simpler postoperative follow-up and a better safety profile is fueling the development of newer surgical procedures. 2008-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372008/548874null XML http://www.modernmedicine.com/modernmedicine/Glaucoma+Feature/Fixed-brimonidine-timolol-combo-appears-safe-effec/ArticleStandard/Article/detail/548861?contextCategoryId=572&ref=25 The fixed combination of brimonidine tartrate 0.2% and timolol maleate 0.5% (Combigan, Allergan) is an effective and well-tolerated substitute treatment for patients whose IOP remains uncontrolled under prostaglandin analog monotherapy or any other fixed combination of hypotensive agents, according to a poster presentation made at the World Ophthalmology Congress. 2008-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372008/548861null XML